- Long-term follow-up data for PADCEV® with KEYTRUDA® in advanced bladder cancer to be featured as oral presentation –
- Updated Phase 1 data on first-in-class integrin beta-6. | April 26, 2023
Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.
- Data presentations demonstrate continued potential of PADCEV® (enfortumab vedotin-ejfv) in multiple types of urothelial cancer Patient-reported outcomes underscore Seagen’s commitment to addressing patients’ needs and quality of life -BOTHELL, Wash. (BUSINESS WIRE) Seagen Inc. (Nasdaq: SGEN) today announced t.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1.